Paget’s Disease of Bone: Deformity, Pain, and Treatment

Bone is a living tissue. It constantly rebuilds itself through a carefully balanced cycle of breakdown and renewal. Old bone breaks down. New bone forms to replace it. This cycle keeps the skeleton strong, structurally sound, and capable of withstanding the forces of daily life. However, when this cycle malfunctions in specific areas of the skeleton, the consequences can be dramatic and disabling.

Paget’s disease of bone is a chronic condition in which the normal bone remodelling cycle goes seriously wrong in one or more localised areas. The cells that break down bone become overactive and work far too fast. The cells that form new bone try to keep up — but the replacement bone they produce is abnormally large, structurally disorganised, weaker than normal bone, and prone to deformity. Over time, affected bones enlarge, soften, bend, and fracture under everyday forces.

Paget’s disease bone deformity pain treatment covers one of the most common metabolic bone disorders in older adults. Furthermore, it often develops silently for years before causing any noticeable symptoms. Consequently, understanding what drives this condition, how to recognise its signs early, and what treatments can halt its progression gives patients and families the knowledge they need to protect bone health and prevent serious long-term complications.

Quick Answer

Paget’s disease of bone is a chronic skeletal disorder in which overactive bone-breaking cells cause abnormal bone regrowth that is enlarged, structurally weak, and prone to deformity. It most commonly affects the pelvis, spine, skull, and leg bones. Bisphosphonate medications effectively suppress the abnormal bone activity and reduce pain and complication risk significantly.

How Bone Remodelling Works — and How Paget’s Disrupts It

Normal Bone Remodelling

Healthy bone maintains itself through a continuous process called remodelling. Two key cell types carry out this process. Osteoclasts break down old or damaged bone tissue — a process called resorption. Osteoblasts then move into the cleared area and deposit new bone tissue to replace what was removed. This cycle operates throughout life in small localised units across the entire skeleton. As a result, virtually all bone in the adult body renews itself roughly every ten years.

The two cell types work in close coordination — linked by chemical signals that keep breakdown and rebuilding in precise balance. When this balance is maintained, bones retain their normal shape, density, and strength. However, when the balance tips in either direction, serious problems follow. For context on what happens when the balance tips toward bone loss, see our article on osteoporosis — how bones lose density and what reverses it.

What Goes Wrong in Paget’s Disease

In Paget’s disease, osteoclasts in specific areas of the skeleton become abnormally overactive. They break down bone far faster than the normal rate — up to ten to twenty times faster in severely affected sites. Furthermore, the overactive osteoclasts are abnormally large and contain far more nuclei than normal, giving them unusual destructive capacity.

Osteoblasts respond to this accelerated breakdown by ramping up new bone formation. However, they cannot match the pace of the overactive osteoclasts. As a result, the replacement bone forms too quickly, without proper organisation, and lacks the carefully aligned structure that gives normal bone its strength. The new bone is enlarged — sometimes dramatically — but paradoxically weaker and more brittle than normal. Consequently, affected bones become thick, structurally chaotic, and mechanically fragile at the same time.

What Causes Paget’s Disease of Bone?

Genetic Factors

Paget’s disease bone deformity pain treatment begins with understanding its causes. The exact trigger for the abnormal osteoclast behaviour remains incompletely understood. However, genetics plays a central and well-established role. Roughly 15 to 30% of people with Paget’s disease have a first-degree relative with the same condition — a familial clustering far higher than chance alone would predict.

Mutations in the SQSTM1 gene — which encodes a protein called sequestosome 1 — are the most commonly identified genetic change in familial Paget’s disease. This protein plays a key role in regulating osteoclast activity. When it is abnormal, osteoclast control breaks down and the cells become overactive. Furthermore, mutations in several other genes affecting osteoclast signalling pathways — including genes in the RANK/RANKL/OPG pathway — contribute to Paget’s disease risk. Consequently, genetic testing is increasingly available for families with multiple affected members.

Viral and Environmental Triggers

Despite the clear genetic contribution, genetics alone does not explain the full picture. Researchers have long suspected that an environmental trigger — most likely a slow-acting viral infection — activates the abnormal osteoclast behaviour in genetically susceptible individuals. Paramyxovirus particles — from virus families including measles and respiratory syncytial virus — have been detected inside the abnormal osteoclasts of Paget’s disease patients in some studies.

However, this viral hypothesis remains controversial. The evidence is inconsistent across different research groups and populations. Moreover, the falling incidence of Paget’s disease in countries where it was previously very common — particularly the United Kingdom, Australia, and New Zealand — suggests that environmental factors changing over recent decades may be contributing to this decline. Consequently, the cause of Paget’s disease is most likely a combination of genetic predisposition and an environmental trigger that has not yet been definitively identified.

Who Is Most at Risk?

Paget’s disease is predominantly a condition of older adults. It rarely develops before the age of 40 and becomes increasingly common with advancing age. Furthermore, it is significantly more common in people of British and northern European ancestry than in Asian or African populations. Men develop Paget’s disease somewhat more frequently than women.

Geographic clustering is striking. Historically, Paget’s disease has been exceptionally common in parts of the United Kingdom, Australia, New Zealand, and parts of Western Europe — while remaining rare in Asia, Africa, and Scandinavia. Moreover, the condition is more common in people whose families emigrated from high-prevalence regions — suggesting that both genetic heritage and shared environmental exposure contribute to risk. Consequently, geographic and family history both inform clinical suspicion when Paget’s disease is considered as a diagnosis.

Symptoms of Paget’s Disease of Bone

The Silent Majority

The majority of people with Paget’s disease have no symptoms at all. The condition is discovered incidentally — through a blood test showing elevated alkaline phosphatase — an enzyme that rises when bone remodelling is accelerated — or through an X-ray taken for an unrelated reason that reveals characteristic bone changes.

This silent presentation is clinically important. Paget’s disease can progress for years without causing any pain or physical change that draws attention. Consequently, many people live with undiagnosed Paget’s disease for a long time before the diagnosis is made. Furthermore, the absence of symptoms does not mean the disease is inactive — bone remodelling disruption continues in the background, progressively altering bone architecture.

Pain, Deformity, and Neurological Effects

When symptoms do develop, bone pain is the most common complaint. The pain arises from the increased vascularity — blood vessel growth — within affected bones, from microfractures within structurally weakened bone tissue, and from secondary arthritis in joints adjacent to Paget-affected bones. Furthermore, the pain is typically deep, aching, and constant — present both during activity and at rest — distinguishing it from purely mechanical joint pain that improves with rest.

Visible bone deformity is one of the most characteristic features of advanced Paget’s disease. The tibia — the shin bone — commonly bows forward and outward. The skull enlarges, and affected individuals may notice that hats no longer fit. Spinal vertebrae affected by Paget’s disease can compress the spinal cord or nerve roots, causing back pain, leg weakness, or numbness. Similarly, skull involvement can compress the nerves supplying the ear — causing hearing loss — or narrow the openings through which brain arteries pass — raising the risk of stroke.

High-output heart failure — a condition in which the heart pumps abnormally large volumes of blood to meet the demands of the highly vascular Paget-affected bone — can develop in patients with extensive skeletal involvement. Moreover, the elevated metabolic activity within severely affected bones significantly increases local blood flow, placing a sustained demand on cardiac output. Consequently, cardiovascular assessment is relevant in patients with widespread Paget’s disease, particularly those with pre-existing heart conditions. For context on how chronic disease affects multiple organ systems simultaneously, see our article on chronic kidney disease — stages, symptoms, and how to slow the decline.

How Doctors Diagnose Paget’s Disease

Blood Tests and Bone Markers

Diagnosing Paget’s disease bone deformity pain treatment begins with a blood test measuring serum alkaline phosphatase — an enzyme produced by osteoblasts during active bone formation. In Paget’s disease, alkaline phosphatase levels are typically markedly elevated — reflecting the dramatically accelerated rate of bone turnover in affected sites. Furthermore, the degree of elevation roughly reflects the extent and activity of the disease — with very high levels suggesting widespread skeletal involvement.

In some patients — particularly those with limited single-site disease — alkaline phosphatase may be only mildly elevated or even within the upper range of normal. In these cases, more specific bone turnover markers — including serum procollagen type 1 N-terminal propeptide — called P1NP — and urinary N-telopeptide — give more sensitive assessment of osteoblast and osteoclast activity respectively. Moreover, these markers are particularly useful for monitoring treatment response over time.

Imaging Studies

Plain X-ray is an essential part of the diagnostic evaluation. Paget-affected bones show characteristic X-ray changes including bone enlargement, coarsened bone trabeculae — the internal scaffolding of bone — thickening of the cortex — the outer shell of the bone — and bowing deformity in long bones such as the femur and tibia. Furthermore, a typical early X-ray finding in the skull is a large area of bone resorption followed by dense new bone formation — a pattern called osteoporosis circumscripta followed by the cotton-wool appearance of new Pagetic bone.

Bone scintigraphy — a nuclear medicine scan that detects areas of high bone metabolic activity — provides a whole-body map of Paget’s disease involvement. It identifies all actively affected skeletal sites simultaneously — including asymptomatic sites that plain X-ray might miss. Consequently, bone scintigraphy followed by targeted X-rays of positive sites gives the most complete picture of disease extent at diagnosis.

CT scanning and MRI provide detailed assessment of specific complications — including spinal cord compression, joint damage, and — when bone sarcoma is suspected — soft tissue extension of disease. Furthermore, MRI is particularly valuable for assessing neurological complications and for excluding malignant transformation in painful lesions that change unexpectedly.

Treatment of Paget’s Disease

Bisphosphonate Medications

Treating Paget’s disease bone deformity pain treatment centres on suppressing the overactive osteoclasts driving the abnormal bone turnover. Bisphosphonate medications — the same class used in osteoporosis treatment — are the cornerstone of Paget’s disease management. They work by binding to the surface of bone and being taken up by osteoclasts during resorption, where they block the internal machinery driving osteoclast activity. As a result, abnormal bone turnover slows dramatically and bone markers return toward normal.

Zoledronic acid — given as a single intravenous infusion — is the most effective bisphosphonate for Paget’s disease and the current gold-standard treatment in most international guidelines. A single infusion achieves biochemical remission — normalisation of alkaline phosphatase — in roughly 90% of patients. Furthermore, the remission achieved with zoledronic acid is durable — lasting five years or more in many patients — making it far superior to older oral bisphosphonates that required repeated dosing. Consequently, a single clinic visit for zoledronic acid infusion now provides years of disease control for most patients.

Oral bisphosphonates — including risedronate and alendronate — remain alternatives for patients who cannot receive intravenous treatment. They require daily or weekly dosing and achieve remission in a lower proportion of patients than zoledronic acid. However, they remain effective options when intravenous access is difficult or when patient preference favours oral treatment.

For broader context on how bisphosphonates work and their role in metabolic bone disease, see our article on osteoporosis — how bones lose density and what reverses it.

Managing Pain and Complications

Pain management is an important component of Paget’s disease care alongside disease-modifying treatment. In many patients, bisphosphonate treatment alone significantly reduces bone pain within weeks to months as disease activity subsides. However, secondary arthritis in joints adjacent to Paget-affected bone may persist after biochemical remission because the joint damage already accumulated does not reverse with bisphosphonate therapy.

Paracetamol and topical NSAIDs provide first-line pain relief for Paget-related joint pain. Oral NSAIDs — used at the lowest effective dose for the shortest necessary period — offer additional relief when topical treatment is insufficient. Furthermore, physiotherapy helps maintain joint mobility, muscle strength, and gait mechanics in patients with deformity or adjacent joint arthritis. Consequently, pain management in Paget’s disease often combines disease control with symptomatic support across several modalities simultaneously.

For context on managing joint pain that coexists with metabolic bone conditions, see our articles on osteoarthritis — inflammation, causes, and what actually helps — and avascular necrosis — when bone tissue dies from lack of blood supply.

Surgical Treatment

Surgery plays an important role in managing the complications of Paget’s disease. Fractures through Paget-affected bone — called pathological fractures — require orthopaedic fixation with rods or plates because the structurally abnormal bone heals poorly without mechanical support. Furthermore, bisphosphonate treatment before and after surgery reduces excessive bleeding — which is a significant risk during surgery on Paget bone because of its high vascularity.

Joint replacement surgery for severe secondary arthritis of the hip or knee produces excellent functional outcomes in Paget’s disease patients, comparable to replacement surgery for primary osteoarthritis. However, the abnormal bone structure and increased vascularity of Paget-affected bone make surgery technically more demanding. Consequently, referral to an orthopaedic surgeon with specific experience in Paget’s disease is recommended for patients requiring operative intervention.

Neurosurgical decompression may be needed for patients with spinal cord or nerve root compression causing progressive weakness or incontinence. Moreover, stapedectomy — surgical treatment of the hearing ossicles in the ear — can improve hearing loss caused by Paget’s disease involvement of the skull bones when medical treatment alone has not restored hearing.

Monitoring and Long-Term Management

Biochemical Monitoring

Long-term follow-up is essential in Paget’s disease because the condition can reactivate after a period of remission. Alkaline phosphatase — or specific bone turnover markers — provide reliable monitoring of disease activity at follow-up visits. Most guidelines recommend measuring alkaline phosphatase every three to six months in the first year after treatment, then annually once stable remission is established.

Rising alkaline phosphatase levels during follow-up signal disease reactivation and the need for retreatment. Furthermore, new symptoms — including new bone pain, neurological changes, or changes in bone shape — should trigger prompt re-evaluation regardless of biochemical markers. Consequently, a combination of symptom monitoring and biochemical surveillance provides the most reliable detection of reactivation between planned appointments.

Rare but Serious Complications

Osteosarcoma — a malignant bone tumour — is a rare but serious complication of Paget’s disease. It develops in fewer than 1% of patients but carries a very poor prognosis. It typically presents as sudden severe pain in a previously stable Paget site, combined with rapid local swelling. Consequently, any sudden unexplained change in pain character or new swelling in a known Paget site requires urgent MRI and specialist review to exclude malignant transformation.

For context on how fibromyalgia-related pain can sometimes overlap with and complicate the assessment of bone pain in older adults, see our article on fibromyalgia — the pain condition that is real, widely misunderstood, and treatable.

When to Seek Medical Help

See a doctor promptly if you develop persistent bone pain — particularly deep, constant pain at rest — progressive deformity of a limb, new hearing loss, leg weakness, or numbness. Furthermore, any person with a known diagnosis of Paget’s disease who develops sudden severe pain in a previously stable site needs urgent medical reassessment to exclude pathological fracture or malignant transformation.

Consequently, regular follow-up appointments — even in the absence of symptoms — allow early detection of disease reactivation and timely treatment before new bone damage accumulates.

Frequently Asked Questions

1. Is Paget’s disease of bone the same as Paget’s disease of the breast?

No. These are two entirely different conditions that share only a name. Paget’s disease of bone is a metabolic skeletal disorder affecting osteoclast and osteoblast activity. Paget’s disease of the breast — also called Paget’s disease of the nipple — is a rare form of breast cancer affecting the skin of the nipple and areola. Furthermore, they have completely different causes, treatments, and outcomes. Consequently, it is important to clarify which condition is being discussed whenever the name Paget’s disease is used in a clinical or educational context.

2. Can Paget’s disease of bone be cured?

Paget’s disease cannot be permanently cured with current treatments. However, bisphosphonate therapy — particularly zoledronic acid — achieves durable biochemical remission in the majority of patients and significantly reduces the risk of complications including fracture, deformity, and hearing loss. Furthermore, treated patients can remain in remission for many years before requiring retreatment. Consequently, the goal of treatment is long-term disease suppression rather than permanent elimination.

3. Does Paget’s disease always cause symptoms?

No. The majority of people with Paget’s disease have no symptoms at all when the condition is diagnosed. In most cases, the diagnosis is made incidentally through blood tests or imaging performed for unrelated reasons. Furthermore, some people live with Paget’s disease for their entire lives without developing significant complications. Consequently, not everyone with Paget’s disease requires immediate treatment — clinical guidelines recommend treating patients with active disease at sites at high risk of complications rather than every person with a positive diagnosis.

4. Does Paget’s disease increase the risk of bone cancer?

Yes, but the risk is very small. Osteosarcoma develops in fewer than 1% of people with Paget’s disease — making it a rare complication even within an already uncommon condition. However, when it does occur, it carries a significantly worse prognosis than osteosarcoma arising in normal bone. Consequently, any sudden unexplained change in pain character or new swelling in a known Paget site should prompt urgent specialist assessment to exclude this rare but serious complication as early as possible.

5. Can younger people develop Paget’s disease?

Paget’s disease is extremely rare in people under 40. It becomes progressively more common with advancing age and is most prevalent in adults over 55. However, a rare juvenile form — called juvenile Paget’s disease — occurs in children and results from mutations in a different gene than adult-onset Paget’s disease. Furthermore, early-onset adult Paget’s disease can occur in genetically susceptible families — particularly those carrying SQSTM1 gene mutations — occasionally presenting in adults in their forties. Consequently, a positive family history of Paget’s disease should lower the threshold for investigation in younger adults with unexplained bone pain or elevated alkaline phosphatase.

Conclusion

Paget’s disease of bone is a chronic and potentially serious skeletal disorder that disrupts the normal cycle of bone breakdown and renewal. The result — enlarged, structurally disorganised, mechanically weakened bone — causes deformity, pain, fractures, and a range of complications that extend from hearing loss to neurological compression.

Paget’s disease bone deformity pain treatment has been transformed by modern bisphosphonate therapy — particularly by a single intravenous infusion of zoledronic acid that achieves durable remission in the majority of patients. Furthermore, early diagnosis — often made through a simple blood test — gives treatment the opportunity to halt disease progression before irreversible bone changes accumulate.

If you or a family member has unexplained bone pain, visible bone deformity, progressive hearing loss, or elevated alkaline phosphatase on a blood test, speak to a healthcare professional about investigation for Paget’s disease without delay. Consequently, catching this condition early and treating it promptly gives bones the best possible chance of remaining strong, stable, and free from the serious complications that untreated Paget’s disease can cause.

References

1. George Paget Thomson: Probing the Mysteries of Quantum Mechanics

2. Osteogenesis imperfecta is a genetic disorder caused by type I collagen mutations resulting in extremely fragile bones prone to fractures, bone deformities, and various systemic complications. 
3. Climate change is already fueling dangerous heat waves, raising sea levels and transforming the oceans. 

Disclaimer

This article adapts publicly available information from WHO’s Musculoskeletal Conditions page. This content is for informational and educational purposes only and does not constitute medical advice. ObserverVoice.com is a news and information platform and not a healthcare provider.